Receiving a delisting notification from Nasdaq is a significant negative development for any publicly traded company. It often leads to a decrease in investor confidence and can negatively impact the stock price in the short term. The announcement of an appeal by Scinai Immunotherapeutics indicates the company is taking steps to address the issues leading to the delisting notification. However, until the appeal's outcome is favorable, the uncertainty is likely to have a negative impact on the stock price.